PEAR THERAPEUTICS TO PARTICIPATE IN 9TH ANNUAL BTIG MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTICS CONFERENCE
BOSTON–(BUSINESS WIRE)–Feb. 2, 2022– Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference, a virtual event taking place February 15 -17. Corey McCann, M.D., Ph.D., President and CEO, will participate in a fireside chat at 2:00 PM ET on Wednesday, February 16. Pear management will also participate in 1×1 meetings.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220202005241/en/
Media and Investors:
Senior Director, Corporate Communications
Source: Pear Therapeutics, Inc.Back